Effect of HMG-CoA reductase inhibitors on chronic allograft rejection

Kidney International, Supplement

Volumn 56, Issue 71, 1999, Pages

  Katznelson, Steven ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

B cell; Nitric oxide; Pravastatin; Simvastatin; T cell; Transplant coronary vasculopathy

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN;

CONFERENCE PAPER; DRUG EFFECT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; VASCULAR SMOOTH MUSCLE; ANIMAL; CHRONIC DISEASE; DISEASE MODEL; GRAFT REJECTION; REVIEW;

ANIMALS; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; GRAFT REJECTION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 0033014599     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. TULLIUS SG, TILNEY NL: Both alloantigen-dependent and -independent factors influence chronic allograft rejection. Transplantation 59:313-318, 1995
2. PAUL LC, FELLSTROM B: Chronic vascular rejection of the heart and the kidney - Have rational treatment options emerged? Transplantation 53:1169-1179, 1992
3. KOBASHIGAWA JA, KATZNELSON S, LAKS H, JOHNSON JA, YEATMAN L, WANG XM, CHIA D, TERASAKI PI, SABAD A, COGERT GA, TRO-SIAN K, HAMILTON MA, HAGE A, DRINKWATER D, STEVENSON LW: Impact of pravastatin on cholesterol lowering, rejection, survival and the development of transplant coronary vasculopathy. N Engl J Med 333:621-627, 1995
4. WENKE K, MEISER B, THIERY J, NAGEL D, VON SCHEIDT W, STEINBECK G, SEIDEL D, REICHART B: Simvastatin reduces graft vessel disease and mortality after heart transplantation: A four-year randomized trial. Circulation 96:1398-1404, 1997
5. KATZNELSON S, WILKINSON AH, KOBASHIGAWA JA, WANG WM, QUA D, OZAWA M, ZHONG HP, HIRATA M, COHEN AH, TERASAKI PI, DANOVITCH GM: The effect of pravastatin on acute rejection after kidney transplantation - A pilot study. Transplantation 61: 1469-1474, 1996
6. ALMOND PS, MATAS A, GILLINGHAM K, DUNN DL, PAYNE WD, GORES P, GRUESSNER R, NAJARIAN JS: Risk factors for chronic rejection in renal allograft recipients. Transplantation 55:752-757, 1993
7. MEISER BM, WENKE K, THIERY J, WOLF S, DEVENS C, SEIDEL D, HAMMER C, BILLINGHAM ME, REICHART B: Simvastatin decreases accelerated graft vessel disease after heart transplantation in an animal model. Transplant Proc 25:2077-2079, 1993
8. MAGARD M, KE B, WANG T, KALDAS F, SEU P, BUSUTTIL RW, IMAGAWA D: The effects of pravastatin on chronic rejection of rat cardiac allografts. Transplantation 65:149-155, 1998
9. KAKKIS JL, KE B, DAWSON S, CHAI W, KALDAS F, SHAU H, SEU P, SAURI H, BUSUITTIL RW, IMAGAWA DK: Pravastatin increases survival and inhibits natural killer cell enhancement factor in liver transplanted rats. J Surg Res 69:393-398, 1997
10. KATZNELSON S, BERRYMAN E, GRIFFEY S, PEREZ RV, GREGORY C: Combined therapy with pravastatin and cyclosporin decreases arterial intimal thickening in a model of severe vascular immune injury. Transplantation 65(Suppl):S38, 1998
11. KATZNELSON S, WANG X, CHIA D, OZAWA M, ZHONG H, HIRATA M, TERASAKI PI, KOBASHIGAWA JA: The inhibitory effects of pravastatin on natural killer cell activity in vivo and cytotoxic T lymphocyte acitivity in vitro. J Heart Lung Transplant 17:335-340, 1998
12. CUTTS JL, BANKURST AD: Suppression of lymphoid cell function in vitro by inhibition of 3-hydroxy-3-methylglutaryl enzyme A reductase by lovastatin. Int J Immunopharm 11:863-869, 1989
13. RUDICH SM, MONGINI PKA, PEREZ RV, KATZNELSON S: HMG-CoA reductase inhibitors pravastatin and simvastatin inhibit human B lymphocyte activation. Transplant Proc 30:992-995, 1998
14. KREUZER J, BADER J, JAHN L: Chemotaxis of the monocyte line U937: Dependence on cholesterol and early mevalonate pathway products. Atherosclerosis 90:203-209, 1991
15. NIWA S, TOTSUKA T, HYASHI S: Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte line. Int J Immunopharmac 18:669-675, 1996
16. WEBER C, ERL W, WEBER K, WEBER P: HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 30:1212-1217, 1997
17. CUTTS JL, BANKHURST AD: Reversal of lovastatin-mediated inhibition of natural killer cell cytotoxicity by interleukin 2. J Cell Physiol 145:244, 1990
18. NEGRE-AMINOU P, VAN VLIET AK, VAN ERCK M, VAN THIEL GC, VAN LEEUEN RE, COHEN LH: Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors: Comparison with other human cell types. Biochim Biophys Acta 1345:259-268, 1997
19. KATZNELSON S, RAMIREZ A, PEREZ RV, WEISS R: Pravastatin and cyclosporine inhibit PDGF-stimulated vascular smooth muscle cell mitogenesis - An investigation of mechanism. Transplant Proc 30: 998-999, 1998
20. KOBASHIGAWA JA, KASISKE BL: Hyperlipidemia in solid organ transplantation. Transplantation 63:331-338, 1997
21. JOHNSON MR: Transplant coronary disease: Nonimmunologic risk factors. J Heart Lung Transplant 11(Suppl):S124-S132, 1992
22. DIMENY E, TUFVESON G, LARSSON E, LITHELL H, SIEGBAHN A, FELLSTROM B: The influence of posttransplant lipoprotein abnor-malities on the early results of renal transplantation. Eur J Clin Invest 23:572-579, 1993
23. COOKE JP: Therapeutic interventions in endothelial dysfunction: Endothelium as a target organ. Clin Cardiol 11(Suppl 2):II-45-II-51, 1997
24. SHEARS LL, KAWAHARADA N, TZENG E, BILLIAR TR, WATKINS SC, KOVESDI I, LIZONOVA A, PHAM SM: Inducible nitric oxide synthase suppresses the development of allograft arteriosclerosis. J Clin Invest 100:2035-2042, 1997
25. LAUFS U, LA FATA V, PLUTZKY J, LIAO JK: Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Circ 97:1129-1135, 1998